Endophthalmitis
The SUSVIMO implant has been associated with a 3-fold higher rate of endophthalmitis than monthly intravitreal injections of ranibizumab. In clinical trials, 2.0% of patients receiving an implant experienced an episode of endophthalmitis.
Patient counseling
Package inserts
Keywords: Susvimo
Updated: October 2021
This information provides a SUMMARY of Black Box data from product labeling and does not address all warnings, precautions, or important safety data found in the product insert. It is NOT intended for use in medical decision-making. Patients and healthcare professionals should always consult the most recent product information insert available from the manufacturer, and contact a physician or care provider with any questions. This table may not be complete and may not include all boxed warnings. It is periodically updated with supplemental information from FDA safety alerts, labeling announcements, and new drug approvals.
Formweb is a product of Rpharmy, LLC.
Visit our website at rpharmy.com for more information on online formularies featuring Black Box Warnings.